Select country set
language
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

Granzyme B Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Granzyme 2, Fragmentin 2, Human lymphocyte protein, Granzyme-B, GrB, GZMB, C11, CTLA-1, Cathepsin G-like 1, CTSGL1, Cytotoxic T-lymphocyte proteinase 2, Lymphocyte protease, HLP, SECT, T-cell serine protease 1-3E
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RAF019R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Cell culture supernatant

Sample Requirements

50 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.7–480 pg/ml

Limit of Detection

0.2 pg/ml

Intra-assay (Within-Run)

CV = 8.5%

Inter-assay (Run-to-Run)

CV = 10.4%

Spiking Recovery

117,00%

Dilution Linearity

88,00%

Summary

Research topic

Apoptosis, Extracellular matrix, Immune Response, Infection and Inflammation, Transplantation

Summary

Granzymes are exogenous serine proteinases (enzymes) that are released from cytoplasmic granules of cytotoxic lymphocytes (CTLs) and NK cells.
The name “granzymes” is derived from: granules + enzymes. These granules contain next to granzymes other proteins including a pore-forming protein (Perforin). Upon binding of the CTL to a target cell (by CTL-receptor and antigen-presenting MHC molecules on the target cell) the contents of the granules are released in the intercellular space where after perforine will “perforate” the target cell membrane by forming transmembrane pores. Through these pores the granzymes can now enter the cytosol of the target cell. Granzyme B activates the intracellular cascade of caspases finally resulting in the killing of the target cells. Also Granzyme A is able to induce apoptosis in the target cell but the molecular mechanisms of the pathway involved need to be clarified.
Percentages of the Granzyme A and B positive CTLs can be determined by flow cytometry and immunocytochemical methods for many disorders.
Not all granzymes enter the target cell, part of them also “leak” in to the peripheral blood and other biological fluids. Detectable amounts of granzymes have been found to circulate in healthy volunteers. These soluble granzymes can be measured by ELISAs.
Viral infections: Increased levels of soluble granzymes have been found with patients suspected of an increased NK cell and CTL-response caused by systemic viral infections such as EBV, HIV, CMV, hepatitis A and Dengue fever.
Lymphomas and carcinomas: It is shown that the presence of a high percentage of Granzyme B positive CTLs in glands of patients suffering from Hodgkin’s disease correlate with a severe prognosis.
Rheumatoid arthritis: Soluble Granzyme A and B is increased in synovial fluid from rheumatoid arthritis and significantly higher than levels in patients with osteoarthrosis.
Transplantation: Granzymes are likely involved in the acute rejection of kidney-transplants, as infiltrating lymphocytes in the rejected kidney strongly express granzymes. Increasing plasma levels of soluble granzymes in patients with a kidney transplants suggest a systemic viral infection, in particular an infection by CMV.

Product References (1)

References

  • Najar M, Fayyad-Kazan M, Meuleman N, Bron D, Fayyad-Kazan H, Lagneaux L.Mesenchymal stromal cells of the bone marrow and natural killer cells: cellinteractions and cross modulation. J Cell Commun Signal. 2018 Dec;12(4):673-688. doi: 10.1007/s12079-018-0448-4. Epub 2018 Jan 19. PubMed PMID: 29350342; PubMedCentral PMCID: PMC6235772. See more on PubMed
Summary References (10)

References to Granzyme B

  • Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest. 2009 Nov;89(11):1195-220. doi: 10.1038/labinvest.2009.91. Epub 2009 Sep 21. PMID: 19770840; PMCID: PMC7102238. See more on PubMed
  • Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA, Froelich CJ, Nice EC, Bird PI. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem. 2005 Jun 24;280(25):23549-58. doi: 10.1074/jbc.M412001200. Epub 2005 Apr 19. PMID: 15843372. See more on PubMed
  • Hiebert PR, Boivin WA, Abraham T, Pazooki S, Zhao H, Granville DJ. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol. 2011 Jun;46(6):489-99. doi: 10.1016/j.exger.2011.02.004. Epub 2011 Feb 18. PMID: 21316440. See more on PubMed
  • Hiebert PR, Wu D, Granville DJ. Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice. Cell Death Differ. 2013 Oct;20(10):1404-14. doi: 10.1038/cdd.2013.96. Epub 2013 Aug 2. PMID: 23912712; PMCID: PMC3770318. See more on PubMed
  • Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev. 2010 May;235(1):159-71. doi: 10.1111/j.0105-2896.2010.00894.x. PMID: 20536562. See more on PubMed
  • Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev. 2003 Jun;193:31-8. doi: 10.1034/j.1600-065x.2003.00044.x. PMID: 12752668. See more on PubMed
  • Parkinson LG, Toro A, Zhao H, Brown K, Tebbutt SJ, Granville DJ. Granzyme B mediates both direct and indirect cleavage of extracellular matrix in skin after chronic low-dose ultraviolet light irradiation. Aging Cell. 2015 Feb;14(1):67-77. doi: 10.1111/acel.12298. Epub 2014 Dec 11. PMID: 25495009; PMCID: PMC4326907. See more on PubMed
  • Rousalova I, Krepela E. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol. 2010 Dec;37(6):1361-78. doi: 10.3892/ijo_00000788. PMID: 21042704. See more on PubMed
  • Shi L, Yang X, Froelich CJ, Greenberg AH. Purification and use of granzyme B. Methods Enzymol. 2000;322:125-43. doi: 10.1016/s0076-6879(00)22013-2. PMID: 10914010. See more on PubMed
  • Trapani JA, Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr Opin Immunol. 2003 Oct;15(5):533-43. doi: 10.1016/s0952-7915(03)00107-9. PMID: 14499262. See more on PubMed
Related Products Docs